New condom materials put to the test: can plastic beat latex?

NCT ID NCT06557499

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial tests two experimental polyurethane condoms (one standard size, one larger) against a standard latex condom. About 600 healthy couples will use each type during vaginal intercourse and report any breakage or slippage. The goal is to see whether the plastic condoms are as reliable as latex, which could give people more options, especially those with latex allergies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
polyurethane male condoms (57 mm and 63 mm)
What this could lead to
If these condoms perform as well as latex ones, they could offer a reliable alternative for people with latex allergies or preferences.
What could go wrong
This is a device trial, not a drug study. The condoms may still break or slip more often than latex, and individual fit and comfort can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

598 people

The number who actually took part.

Started

Aug 2024

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Both partners participating must provide written informed consent. 2. Couples must include a male and female within a heterosexual couple and be between 18 - 60 years of age inclusive. 3. Both partners must be willing to respond to questions about their reproductive and contraceptive history and use of condoms during interviews and respond to self-administered questionnaires as per instructions. 4. Both partners must agree to answer the questions in the condom use questionnaires and two scales as soon as possible and within 2 (+6) hours following each coital act. 5. Both partners must be generally healthy and in a mutually monogamous heterosexual relationship - current relationship ≥ 3 months. 6. All couples must be averaging one act of intercourse weekly, agree to have penile-vaginal intercourse with a frequency sufficient to meet CIP requirements (a minimum of 5 coital acts over 5 weeks per assessment period-). 7. The female partner must also use an established (as agreed by the Investigator) other highly effective form of non-barrier contraception, unless post-menopausal (confirmed menopausal prior to screening, amenorrhea for at least 12 months after cessation of exogenous hormone treatment) in which case no second form of contraception is required. Highly effective non-barrier contraception includes oral contraceptive (oestrogen and progestogen or progestogen-only hormonal contraception associated with inhibition of ovulation), intra-uterine device (IUD) or intra-uterine system (IUS), hormonal implant, injectables, patch and or sterilization of at least one partner (i.e., bilateral tubal ligation, vasectomy deemed medically successful). 8. Both partners must be able to understand instructions for correct use of condoms. 9. Both partners must have an adequate level of literacy to understand and to be able to answer the questionnaires. 10. Both partners must agree to use only the investigational condoms during the time of participation. 11. Participants must agree to use the penis measuring kit provided to measure the erect penis at investigation start. 12. Both partners must agree not to use drugs or non-investigational devices that can affect sexual performance. 13. Both partners must have no known sexually transmitted infections including Human Immunodeficiency Virus (HIV) / acquired immune deficiency syndrome (AIDS) (medical history via self-report) (uncomplicated Herpes simplex virus (HSV) and positive Human papillomavirus (HPV) which areis asymptomatic may be included in the investigation study in the opinion of the Investigator). 14. Both partners must agree to use only lubricant(s) provided for the duration of investigation. 15. Both partners must agree not to wear any genital piercing jewellery for the duration of the clinical investigation. 16. Both partners must have no past medical history of any health condition (self-reported) that, in the opinion of the Investigator, would be considered clinically relevant. 17. Couples must have a compatible electronic device with internet access which they are willing to upload questionnaire data to the web-based platform throughout the investigation. 18. Both partners will be available for follow-up. Exclusion Criteria: 1. Either partner is or becomes aware of an allergy or sensitivity to the ingredients of any of the products, including the test or control condoms or any lubrication products provided. 2. Either partner has been receiving daily treatment for their pre-existing skin condition (for example, severe eczema/psoriasis) within the three months prior to the screening for this study. 3. Female partner that is pregnant or desires to become so while participating in investigation, (females of childbearing potential must have a negative pregnancy test as part of screening). 4. Any couple undergoing any form of fertility treatment such as in-vitro fertilisation. 5. Either partner needs to use condoms for sexually transmitted infection (STI) protection (e.g., discordance for Human Immunodeficiency Virus (HIV) or herpes). 6. Either partner has previous or planned genital surgery that in the opinion of the Investigator would consider the participant unsuitable to participate in the clinical investigation (e.g., laser for abnormal smear). 7. Either partner are commercial sex workers. 8. Either partner are itinerant persons who will be unable to complete the clinical investigation (e.g., migrant farm workers). 9. Couples that in the opinion of the Investigator, would be unable to complete the investigation. 10. Male partners that have known erectile or ejaculatory dysfunction in the past month. 11. Either partner requires to use/ is using medication or preparations that are applied topically to the genitalia area or intravaginally, other than that supplied for the investigation. 12. A female partner that has been diagnosed with or treated for vaginal complaints (including vaginal dryness) in the previous 3 months which, in the opinion of the Investigator, deems the partner unsuitable for the investigation. 13. Either partner uses any medication which in the investigator's opinion may interfere with the use of condoms. 14. A male partner with abnormal penile anatomy or genital lesion (e.g., balanoposthitis) that would, in the opinion of the Investigator, affect the ability to keep the condom in place during intercourse. 15. Either partner is suffering from any health conditions (self-reported) or any condition which could, in the opinion of the Investigator, affect the outcome of the investigation or affect their safety if they participate. 16. Either partner have participated in a clinical trial in the previous month which could, in the opinion of the Investigator, affect the outcome of the investigation. 17. Either partner is an employee of the investigational Sponsor or affiliated with the clinical research centre (i.e., enrolment of the Investigator, his/ her family members, employees and other dependent persons). 18. Either partner has a recent history of drug/alcohol abuse within the previous 12 months. 19. Either partner has an inability to follow the procedures of the investigation, (e.g., due to language problems, psychological disorders, health conditions such as dementia). 20. Either partner is unable, in the opinion of the Investigator, to fully comply with the investigation requirements.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Contraception are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Essential Access Health -Los Angeles

    Los Angeles, California, 90017, United States

  • Essential Access Health-Berkeley

    Berkeley, California, 90010, United States

  • Essential Acess Health- Seattle

    Seattle, Washington, 98005, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.